Skip to content
10-Q

Quarterly Report

ANEBULO PHARMACEUTICALS, INC. ANEB

0001493152-25-022350

← back to feed
Filed
Nov 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Nov 7, 2025 41.08M sh
Shares Diluted Q1 2026 · Sep 30, 2025 41.08M sh
Shares Diluted Q1 2026 · Sep 30, 2024 25.93M sh
Operating Cash Flow Q1 2026 · Sep 30, 2025 −$1.27M
Operating Cash Flow Q1 2026 · Sep 30, 2024 −$1.69M
Cash And Equivalents Q1 2026 · Sep 30, 2025 $10.35M
Cash And Equivalents Q1 2026 · Jun 30, 2025 $11.63M
Stockholders Equity Q1 2026 · Sep 30, 2025 $9.74M
Stockholders Equity Q1 2026 · Jun 30, 2025 $11.66M
Stockholders Equity Q1 2026 · Sep 30, 2024 $1.9M
Stockholders Equity Q1 2026 · Jun 30, 2024 $3.81M
Total Liabilities Q1 2026 · Sep 30, 2025 $963.82K
Total Liabilities Q1 2026 · Jun 30, 2025 $487.69K
Current Assets Q1 2026 · Sep 30, 2025 $10.54M
Current Assets Q1 2026 · Jun 30, 2025 $11.96M
Total Assets Q1 2026 · Sep 30, 2025 $10.7M
Total Assets Q1 2026 · Jun 30, 2025 $12.15M
Eps Diluted Q1 2026 · Sep 30, 2025 −$0.05
Eps Diluted Q1 2026 · Sep 30, 2024 −$0.08
Eps Basic Q1 2026 · Sep 30, 2025 −$0.05
Eps Basic Q1 2026 · Sep 30, 2024 −$0.08
Sga Expense Q1 2026 · Sep 30, 2025 $1.45M
Sga Expense Q1 2026 · Sep 30, 2024 $1.1M
Rd Expense Q1 2026 · Sep 30, 2025 $809.99K
Rd Expense Q1 2026 · Sep 30, 2024 $1.31M
Net Income Q1 2026 · Sep 30, 2025 −$2.16M
Net Income Q1 2026 · Sep 30, 2024 −$2.2M
Operating Income Q1 2026 · Sep 30, 2025 −$2.26M
Operating Income Q1 2026 · Sep 30, 2024 −$2.41M